Buch, Englisch, 344 Seiten, Previously published in hardcover, Format (B × H): 152 mm x 229 mm, Gewicht: 499 g
Buch, Englisch, 344 Seiten, Previously published in hardcover, Format (B × H): 152 mm x 229 mm, Gewicht: 499 g
Reihe: Methods in Molecular Medicine
ISBN: 978-1-61737-421-0
Verlag: Humana Press
A timely primer on the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Antisense Therapeutics.- Antisense Inhibition.- Cardiovascular.- Local Application of Antisense for Prevention of Restenosis.- Antisense Therapeutics for Hypertension.- Antisense Strategies for the Treatment of Heart Failure.- Cancer.- Clinical Studies of Antisense Oligonucleotides for Cancer Therapy.- Antisense Therapy in Clinical Oncology.- Radionuclide-Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer.- uppression of Pancreatic and Colon Cancer Cells by Antisense K-ras RNA Expression Vectors.- Induction of Tumor Cell Apoptosis and Chemosensitization by Antisense Strategies.- Utility of Antioncogene Ribozymes and Antisense Oligonucleotides in Reversing Drug Resistance.- Blood—Brain Barrier.- Transport of Antisense Across the Blood-Brain Barrier.- Dermal.- Transdermal Delivery of Antisense Oligonucletoides.- Drugs.- Antisense Strategies for Redirection of Drug Metabolism.- Gastrointestinal.- Antisense Oligonucleotide Treatment of Inflammatory Bowel Diseases.- Hepatitis.- Optimizing Electroporation Conditions for Intracellular Delivery of Morpholino Antisense Oligonucleotides Directed Against the Hepatitis C Virus Internal Ribosome Entry Site.
